Brent Carroll, DO
Family Medicine · Cumming, GANPI 1528262045
Payments from drug & device makers
Across 267 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$711
- Lilly USA, LLC$286
- Tris Pharma Inc$256
- Novo Nordisk$249
- Eisai Inc.$209
- Pfizer$201
- plus $3K from 33 others
What the payments were for
- Food & beverage$4,517100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $711 |
| Lilly USA, LLC | 15 | $286 |
| Tris Pharma Inc | 14 | $256 |
| Novo Nordisk | 15 | $249 |
| Eisai Inc. | 16 | $209 |
| Pfizer | 12 | $201 |
| Amgen | 11 | $193 |
| Verity Pharmaceuticals Inc. | 8 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $191 |
| Merck | 11 | $173 |
| Antares Pharma, Inc. | 10 | $167 |
| Teva Pharmaceuticals USA, Inc. | 9 | $156 |
| Aytu Biopharma, Inc. | 6 | $120 |
| Merz North America, Inc. | 1 | $115 |
| Novartis | 6 | $115 |
| AstraZeneca | 8 | $112 |
| Neos Therapeutics, LP | 6 | $104 |
| Idorsia Pharmaceuticals US Inc | 5 | $98 |
| Biohaven Pharmaceuticals, Inc. | 4 | $90 |
| Supernus Pharmaceuticals, Inc. | 6 | $85 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Noven Therapeutics, LLC | 4 | $82 |
| Abbott | 3 | $65 |
| Bausch Health US, LLC | 3 | $61 |
| Clarus Therapeutics Inc. | 3 | $57 |
| Corium, LLC | 2 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Gilead | 2 | $46 |
| Exact Sciences | 2 | $32 |
| Acella Pharmaceuticals, LLC | 1 | $25 |
| Tolmar, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| GSK | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$4,532 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 164 | $174,663 |
| Diclofenac Sodium | 29 | $28,786 |
| JardianceEmpagliflozin | 16 | $26,112 |
| OzempicSemaglutide | 15 | $17,512 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $15,649 |
| EliquisApixaban | 20 | $14,042 |
| XareltoRivaroxaban | 13 | $11,969 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 39 | $7,945 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,067 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16 | $4,638 |
| Lidocaine | 22 | $4,244 |
| ProgesteroneProgesterone, Micronized | 81 | $2,976 |
| Testosterone Cypionate | 35 | $2,128 |
| SynthroidLevothyroxine Sodium | 18 | $2,115 |
| Np ThyroidThyroid,pork | 28 | $1,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $286 | $174,663164 claims |
| Boehringer IngelheimJardiance | $21 | $26,11216 claims |
| Novo NordiskOzempic | $249 | $17,51215 claims |
| MerckJanumet Xr | $173 | $15,64919 claims |
| PfizerEliquis | $201 | $14,04220 claims |
| GSKShingrix, Arexvy | $17 | $12,58355 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $191 | $6,06716 claims |
| AbbVieSynthroid, Armour Thyroid | $711 | $3,37234 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $25 | $1,69828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cumming
- Sheba NaqviCumming$673K
- Raymond EasleyCumming$293K
- Nadine Halliburton-FosterCumming$219K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.